Lates News

According to the AI Fast News of Every Macro, Dongwu Securities issued a research report on March 28, giving Lijiu Group (000513.SZ) a "buy" rating. The rating reasons mainly include: 1) the biological products, traditional Chinese medicine sector, and overseas growth rate are good by 2025, and the overall performance meets expectations; 2) the layout of innovative drugs and biopharmaceutical pipeline is accelerating, with single products worth more than 1 billion yuan being listed one after another. (Daily Economic News)